Norman Wolmark

Also affiliated with UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NRG Oncology, NSABP Foundation

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 35 papers. Top paper: “Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database”.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database

Annals of Oncology(2020)10.1016/j.annonc.2019.12.007

N/A

1.4DataRank · unranked

34 citations

Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts +11 more

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

New England Journal of Medicine(2025)10.1056/nejmoa2414859

N/A

1.2DataRank · unranked

93 citations

Hanna Bandos, Julia White, Thomas B. Julian, Atif J. Khan, Simona F. Shaitelman +23 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0.832DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Breast Cancer Research and Treatment(2022)10.1007/s10549-021-06417-y

N/A

0.593DataRank · unranked

10 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.7

N/A

0.561DataRank · unranked

41 citations

Greg Yothers, Osama E. Rahma, Theodore S. Hong, Marcia M. Russell, Y. Nancy You +14 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps613

N/A

0.520DataRank · unranked

31 citations

Stewart Anderson, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +11 more

Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae188

N/A

0.444DataRank · unranked

11 citations

Neil Carleton, Stewart Anderson, Priya Rastogi, Adrian V. Lee, Marija Balić +4 more

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab187

N/A

0.434DataRank · unranked

17 citations

Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont +16 more

Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.508

N/A

0.345DataRank · unranked

9 citations

Stewart Anderson, Kalliopi P. Siziopikou, Douglas W. Arthur, Thomas B. Julian, Rachel Rabinovitch +15 more

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps212

N/A

0.312DataRank · unranked

7 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +8 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3643

N/A

0.208DataRank · unranked

3 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +9 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3634

N/A

0.104DataRank · unranked

1 citations

Yu Guan, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin +10 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.8

N/A

0DataRank · unranked

32 citations

Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker +10 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad078

N/A

0DataRank · unranked

20 citations

Hanna Bandos, Priya Rastogi, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps623

N/A

0DataRank · unranked

6 citations

Reena S. Cecchini, Eleanor Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz +12 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps260

N/A

0DataRank · unranked

0 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +10 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor–positive breast cancer.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.1556

N/A

0DataRank · unranked

0 citations

Ming Chen, Tanner J. Freeman, Nicolas Stransky, Md. Samiur Rahman, Mark Miglarese +14 more

Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)

Research Square(2021)10.21203/rs.3.rs-841103/v1

N/A

0DataRank · unranked

3 citations

Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher +13 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more